Eupraxia Pharmaceuticals (EPRX) Earnings Date, Estimates & Call Transcripts $5.15 -0.12 (-2.26%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eupraxia Pharmaceuticals Earnings Summary Eupraxia Pharmaceuticals issued Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.26, which missed the consensus estimate of -$0.21 by $0.05. With a trailing EPS of -$0.85, Eupraxia Pharmaceuticals' earnings are expected to grow next year, from ($0.67) to ($0.60) per share. Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportEPRX Upcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Upcoming Q3 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Aug. 12) -$0.21 Actual EPS (Aug. 12) -$0.26 Missed By -$0.05 Get Eupraxia Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataEPRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Eupraxia Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ2 20251-$0.21-$0.21-$0.21Q3 20251-$0.20-$0.20-$0.20Q4 20251-$0.17-$0.17-$0.17 Eupraxia Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------8/12/2025Q2 2025-$0.21-$0.26 -$0.05-$0.26--5/6/2025Q1 2025-$0.19-$0.21 -$0.02-$0.21--3/20/2025Q4 2024-$0.20-$0.21 -$0.01-$0.21--11/7/2024---$0.17--$0.17--8/7/2024Q2 2024--$0.17--$0.17--5/8/2024Q1 2024--$0.21--$0.21--4/1/2024Q4 2023--$0.17--$0.17--11/14/2023Q3 2023--$0.26--$0.26-- Eupraxia Pharmaceuticals Earnings - Frequently Asked Questions When is Eupraxia Pharmaceuticals' earnings date? Eupraxia Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on EPRX's earnings history. Did Eupraxia Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Eupraxia Pharmaceuticals (NASDAQ:EPRX) missed the analysts' consensus estimate of ($0.21) by $0.05 with a reported earnings per share (EPS) of ($0.26). Learn more on analysts' earnings estimate vs. EPRX's actual earnings. How much profit does Eupraxia Pharmaceuticals generate each year? Eupraxia Pharmaceuticals (NASDAQ:EPRX) has a recorded net income of -$25.50 million. EPRX has generated -$0.85 earnings per share over the last four quarters. What is Eupraxia Pharmaceuticals' EPS forecast for next year? Eupraxia Pharmaceuticals' earnings are expected to grow from ($0.67) per share to ($0.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies Tango Therapeutics Earnings Results ArriVent BioPharma Earnings Results Oculis Earnings Results Niagen Bioscience Earnings Results Dianthus Therapeutics Earnings Results Phathom Pharmaceuticals Earnings Results Gyre Therapeutics Earnings Results Nurix Therapeutics Earnings Results Amylyx Pharmaceuticals Earnings Results Mind Medicine (MindMed) Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures This page (NASDAQ:EPRX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access